Article thumbnail

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

By Muge Akmansu, Suleyman Buyukberber, Sevilay Iren, Umut Demirci, Gul Kanyilmaz, Ugur Coskun and Huseyin Bora

Abstract

We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and annual mean survival rate is 59.3%

Topics: Published: December 2010
Publisher: S. Karger AG
OAI identifier: oai:pubmedcentral.nih.gov:3100271
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A phase 3 randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
  2. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.
  3. al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
  4. (2006). al: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (EXTREME).
  5. al: Classification and management of skin, hair, nail and mucosal side effects of epidermal growth factor receptor (EGFR) inhibitors, review.
  6. al: Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.
  7. al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
  8. al: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck.
  9. al: Randomized phase 3 evaluation of cisplatin plus fluorouracil vs. cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
  10. (2005). al: Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck
  11. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
  12. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.
  13. (2008). et al: Overview of the Efficacy of Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Patients Who Previously Failed Platinum-Based Therapies.
  14. (2005). Medical treatment in head and neck cancer. Ann Oncol
  15. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase 2 trial from an Italian cooperative group.
  16. Phase 1 study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
  17. Reirridation alternating with docetaxel and cisplatin in inoperable recurrence of head and neck cancer: a prospective phase 1/2 trial.
  18. Tortora G: EGFR antagonists in cancer treatment.
  19. Twice-daily reirradiation for recurrent and second primary head-andneck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
  20. (2008). Vermorken JB: Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther
  21. Xidakis E, et al: Combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase 2 feasibility study.